BD1 has proven to be able to undertake non-invasive testing to...

BD1 has proven to be able to undertake non-invasive testing to breast cancer and potentially other forms of cancer to be proven in future (This is speculative). This will very likely lead to repeat sales where both women and men are encouraged to get checked every few years. The average person will likely get checked more than 10 times in their lives (assuming one check every 5 years which is conservative).

We all saw how BIT ran, and this should be an indication as to how BD1 should run. It's timeframe to deploy to market is significantly less than BIT. Revenues are just around the corner. This is by no means a down ramp of BIT, they are both taking on huge markets and these recent announcements have transformed both of these companies. BIT ran to 44.5c which is a market cap of approx. 230m and is currently trading at approx 113m for market cap. BD1 is currently at a market cap of 46m.